Fig. 1From: Abiraterone acetate for chemotherapy-naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factorsmCRPC patients in the AA + prednisone group had significantly longer survivals than those in prednisone groupBack to article page